ProCE Banner Activity

Advances in Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing

Watch this interactive, on-demand Webcast led by George D. Demetri, MD, and featuring an expert panel discussing best practices in testing for NTRK fusions in solid tumors, current evidence supporting the use of approved TRK inhibitors, and emerging topics, including TRK inhibitor resistance and second-generation agents.

Released: August 21, 2020

Expiration: August 20, 2021

No longer available for credit.

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Pashtoon M. Kasi

Pashtoon M. Kasi, MD, MS

Director 
Colon Cancer Research 
Weill Cornell Medicine
Director 
Liquid Biopsy Research 
Englander Institute of Precision Medicine 
New York, New Yotk

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Genentech TEXT Only

Learning Objectives

  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in a range of cancers harboring NTRK fusions
  • Formulate strategies for using TRK inhibitors in clinical practice
  • Develop treatment strategies for patients who develop acquired resistance to first-generation TRK inhibitor therapy
  • Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors

Program Director Disclosure

Program Director

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received consulting fees from AbbVie, AdaptImmune, Bayer, Bessor, Blueprint Medicines, Caprion/HistoGeneX, Caris Life Sciences, Champions Biotechnology, Daiichi-Sankyo, EMD Serono, Epizyme, Erasca, G1 Therapeutics, GlaxoSmithKline, ICON, Ignyta, Janssen, Loxo Oncology, Merrimack, Mirati, MJ Hennessey/OncLive, Novartis, PharmaMar, Pfizer, Polaris, RELAY Therapeutics, Roche/Genentech, Sanofi, Translate BIO, WCG/Arsenal Capital, and ZioPharm and royalties paid to his institution from Novartis.

Faculty Disclosure

Primary Author

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, BergenBio, Blueprint Medicines, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, MORE Health, Pfizer, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Foundation Medicine; funds for research support paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and royalties from Wolters Kluwer.

Pashtoon M. Kasi, MD, MS

Director 
Colon Cancer Research 
Weill Cornell Medicine
Director 
Liquid Biopsy Research 
Englander Institute of Precision Medicine 
New York, New Yotk

Pashtoon Kasi, MD, has disclosed that he has received consulting fees from Foundation Medicine, Ipsen, Natera, and Taiho (paid to his institution) and funds for research support from Amgen, Array, AstraZeneca, BTG, Clovis, and RenovoRx.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.